Why Indian drugmakers are losing pricing power in the US
Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue.

Read at Mint(opens in a new tab)
Full coverage
Why Indian drugmakers are losing pricing power in the US (opens Mint in a new tab)
Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment…


